Myocardial infarction with non-obstructive coronary arteries (MINOCA) accounts for 6–10 % of all acute myocardial infarctions (MI), carries a non-trivial long-term risk of major adverse cardiovascular events (MACE), and disproportionately affects women and younger patients [1]. Malignancy appears to be overrepresented in selected MINOCA cohorts: a meta-analysis reported malignancy in 2.5 % of MINOCA patients at presentation [2], whereas a tertiary cardio-oncology registry reported active cancer in 29.2 % of MINOCA versus 12.0 % of obstructive MI (MI-CAD) [3].
